Clinical use of anti-TNF-α biological agents: A guide for GPs

Australian Family Physician

Volumn 36, Issue 12, 2007, Pages 1035-1038

  Chang, John ^a   Girgis, Laila ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; AUSTRALIA; DRUG ANTAGONISM; DRUG EFFECT; DRUG MONITORING; FEMALE; GENERAL PRACTITIONER; HUMAN; MIDDLE AGED; PRIMARY HEALTH CARE; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUSTRALIA; DRUG MONITORING; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PHYSICIANS, FAMILY; PRIMARY HEALTH CARE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38449113617     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust 2005;183:205-8.
2. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34:819-36.
3. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor (alpha) (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2005;64(Suppl 4):2-14.
4. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10:1-258.
5. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005;34:7-11.
6. QuantiFERON - TB Gold. Product information, Cellestis.
7. Botsios C. Safety of tumour necrosis factor and interleukin- 1 blocking agents in rheumatic diseases. Autoimmun Rev 2005;4:162-70.
8. Day R. Adverse reactions to TNF-αlpha inhibitors in rheumatoid arthritis. Lancet 2002;359:540-1
9. RA patients exposed to TNF antagonists are not at increased risk of malignant lymphomas compared to other RA patients. Abstract THU124 EULAR 2007.
10. Bongartz T, Sutton A, Sweeting M, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275-85.